The CHMP gives a positive opinion to Eli Lilly's Jaypirca in patients with relapsed or refractory CLL in a post-BTK inhibitor setting.

In the oncology segment, Pirtobrutinib (Jaypirca) received accelerated approval for chronic lymphocytic leukemia in the U.S. in 2023, and Mantle cell lymphoma in the U.S. in 2023, the EU in 2023, and ...

Following a flurry of activity at this month’s meeting of the European Medicines Agency’s Committee for Medicinal Products ...

Surge Copper Corp. ("Surge" or the "Company") announces the grant of equity-based incentive awards under its Share Compensation Plan. The Company has awarded 4,583,334 restricted share units (RSUs) to ...

Eli Lilly said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended expanded approval of its Jaypirca cancer drug in certain patients with chronic lymphocytic ...

The Board of Directors of MVB Financial Corp. ("MVBF" or "MVB Financial") has announced the appointment of Vic Maculaitis as a Member of the Board. "With more than 20 years of professional experience ...

Eli Lilly (LLY) and Company announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive ...

"Unsurprisingly, pirtobrutinib [Jaypirca, Eli Lilly & Co.] was superior to the comparator arm in terms of progression-free survival," Woyach, professor in the division of hematology at The Ohio ...

Jaypirca binds BTK noncovalently, but is still subject to acquired resistance. By contrast, Nurix’s BTK degraders do not require covalent and prolonged binding to BTK to trigger degradation ...

In the past two years, Lilly has received approvals for several new drugs like Kisunla, Omvoh and Jaypirca. Its new drugs contributed significantly to its top-line growth in 2024. Lilly is also making ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Eli Lilly and ...